Necitumumab Fails to Improve Survival in Lung Cancer (NSCLC)
the Cancer Therapy Advisor take:
According to a new study published in the journal The Lancet Oncology, researchers have found that the addition of necitumumab to cisplatin and pemetrexed did not increase survival of previously untreated patients with stage IV non-squamous non-small cell lung cancer (NSCLC).
Necitumumab is an investigational second-generation recombinant human immunoglobulin G1 EGFR monoclonal antibody.
For the international, open-label, controlled phase III study, researchers enrolled 633 patients with previously untreated non-squamous NSCLC and randomly assigned them to receive either cisplatin 75mg/m2 and pemetrexed 500mg/m2 on day 1 of a 3-week cycle for up to 6 cycles alone, or with necitumumab 800mg on days 1 and 8 until disease progression or unacceptable toxicity.
Results showed a median overall survival of 11.3 months (95% CI: 9.5 - 13.4) for the necitumumab group compared with 11.5 months (10.1 - 13.1) in the chemotherapy alone group (HR = 1.01; 95% CI: 0.84 - 1.21; P = 0.96).
The necitumumab group also experienced a higher incidence of severe adverse events, including death, versus the chemotherapy alone group.
The findings suggest that necitumumab is not likely to provide benefit to patients with previously untreated stage IV non-squamous NSCLC when used in combination with cisplatin and pemetrexed.
Addition of necitumumab to cisplatin and pemetrexed did not increase survival in stage IV non-squamous NSCLC.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Calcium and Cancer
- Checkpoint Inhibition in Multiple Myeloma After Pembrolizumab-related Clinical Trial Deaths
- Atezolizumab Monotherapy Effective in PD-L1 Non-small Cell Lung Cancer
- Pembrolizumab Prolongs Overall Survival Compared With Ipilimumab in Melanoma
- Cabozantinib Effective as Salvage Therapy in Thyroid Cancer
- Everolimus Maintains Quality of Life in Neuroendocrine Tumors
- High Dose Vitamin B Supplements Should Not Be Taken for Lung Cancer Prevention
- Telomere Length May Predict Renal Cell Carcinoma Risk in Patients with VHL
- Platinum Therapy Should Not Be Delayed in Ovarian Cancer Relapse
- Identifying Frail Patients With Multiple Myeloma Improves Treatment Selection